Pharmstandard OJSC specifies details on a possible acquisition

Pharmstandard OJSC specifies details on a possible acquisition

Moscow, 9 July 2013 - Pharmstandard OJSC (LSE: PHST IL, RTS: PHST RU) ("Pharmstandard" or the "Company") would like to inform that the target of a possible acquisition, which the Company is in advanced discussions on, is BEVER PHARMACEUTICAL PTE LTD (Singapore) ("Bever Pharma").

The Company is contemplating to acquire 100% of shares in Bever Pharma for USD630 million.

As indicated before, this acquisition will be subject to approval by the Company's shareholders at the extraordinary shareholder meeting which will take place on 17 August 2013.

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.